Symbols / QTTB $6.38 +4.42% Q32 Bio Inc.
QTTB Chart
About
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 93.34M |
| Enterprise Value | 60.38M | Income | 29.82M | Sales | 53.74M |
| Book/sh | 3.27 | Cash/sh | 3.30 | Dividend Yield | — |
| Payout | 0.00% | Employees | 24 | IPO | — |
| P/E | 2.64 | Forward P/E | -1.19 | PEG | — |
| P/S | 1.74 | P/B | 1.95 | P/C | — |
| EV/EBITDA | 3.49 | EV/Sales | 1.12 | Quick Ratio | 4.31 |
| Current Ratio | 4.85 | Debt/Eq | 36.52 | LT Debt/Eq | — |
| EPS (ttm) | 2.42 | EPS next Y | -5.36 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-10 06:00 | ROA | 13.71% |
| ROE | 125.06% | ROIC | — | Gross Margin | 64.35% |
| Oper. Margin | 85.38% | Profit Margin | 55.49% | Shs Outstand | 14.63M |
| Shs Float | 6.30M | Short Float | 5.98% | Short Ratio | 1.60 |
| Short Interest | — | 52W High | 8.04 | 52W Low | 1.34 |
| Beta | -1.02 | Avg Volume | 244.07K | Volume | 166.63K |
| Target Price | $14.33 | Recom | None | Prev Close | $6.11 |
| Price | $6.38 | Change | 4.42% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$14.33
Mean price target
2. Current target
$6.38
Latest analyst target
3. DCF / Fair value
$5.57
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.38
Low
$10.00
High
$20.00
Mean
$14.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-25 | init | HC Wainwright & Co. | — → Buy | $13 |
| 2025-03-12 | main | Wells Fargo | Equal-Weight → Equal-Weight | $15 |
| 2025-02-11 | down | BMO Capital | Outperform → Market Perform | $3 |
| 2025-02-11 | down | Piper Sandler | Overweight → Neutral | $4 |
| 2024-12-12 | main | BMO Capital | Outperform → Outperform | $22 |
| 2024-12-12 | down | Guggenheim | Buy → Neutral | — |
| 2024-12-11 | main | Oppenheimer | Outperform → Outperform | $20 |
| 2024-12-11 | main | Piper Sandler | Overweight → Overweight | $20 |
| 2024-12-11 | down | Wells Fargo | Overweight → Equal-Weight | $16 |
| 2024-12-11 | down | Leerink Partners | Outperform → Market Perform | $9 |
| 2024-12-11 | down | Raymond James | Strong Buy → Outperform | $22 |
| 2024-12-06 | init | BMO Capital | — → Outperform | $64 |
| 2024-10-24 | init | Raymond James | — → Strong Buy | $90 |
| 2024-09-11 | init | Wells Fargo | — → Overweight | $95 |
| 2024-06-17 | init | Guggenheim | — → Buy | $100 |
| 2024-05-21 | init | Leerink Partners | — → Outperform | $54 |
| 2024-04-11 | init | Oppenheimer | — → Outperform | $50 |
| 2024-04-02 | init | Piper Sandler | — → Overweight | $45 |
- Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire ue, 10 Mar 2026 07
- Wall Street Analysts See a 103.55% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High? - finance.yahoo.com Fri, 13 Mar 2026 07
- $QTTB stock is up 17% today. Here's what we see in our data. - Quiver Quantitative ue, 10 Mar 2026 07
- Q32 Bio: Bempikibart Keeps The Alopecia Areata Bull Case Alive (NASDAQ:QTTB) - Seeking Alpha Mon, 30 Mar 2026 12
- Q32 Bio (QTTB) One Off Driven Q4 Profit Challenges Earnings Decline Narrative - simplywall.st hu, 12 Mar 2026 07
- QTTB Should I Buy - Intellectia AI Wed, 01 Apr 2026 04
- Q32 Bio (QTTB) Upgraded to Strong Buy: Here's What You Should Know - finance.yahoo.com hu, 19 Mar 2026 07
- QTTB Stock Explodes Nearly 95%: Akebia Deal Transforms Q32 Bio’s Future - Bitget ue, 02 Dec 2025 08
- H.C. Wainwright reiterates Q32 Bio stock rating with $13 target - Investing.com ue, 10 Mar 2026 07
- Q32 Bio Trades At Lows While Betting On Immune Breakthroughs - Finimize ue, 07 Oct 2025 07
- Q32 Bio Announces $10.5 Million Registered Direct Offering - PR Newswire ue, 17 Feb 2026 08
- Q32 Bio Insiders Benefit From Selling Stock At US$2.86 - simplywall.st Sun, 07 Dec 2025 08
- Q32 Bio Stock (QTTB) Opinions on ADX-097 Asset Sale | QTTB Stock News - Quiver Quantitative Mon, 01 Dec 2025 08
- Does Q32 Bio (QTTB) Have the Potential to Rally 97.66% as Wall Street Analysts Expect? - finance.yahoo.com Mon, 30 Mar 2026 13
- Q32 Bio Sells Complement Inhibitor ADX-097 - PR Newswire Mon, 01 Dec 2025 08
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
53.74
|
0.00
+100.00%
|
-6.65
-200.00%
|
6.65
|
| Operating Revenue |
|
53.74
|
0.00
+100.00%
|
-6.65
-200.00%
|
6.65
|
| Operating Expense |
|
36.84
-44.28%
|
66.10
+58.88%
|
41.60
-9.31%
|
45.88
|
| Research And Development |
|
19.16
-60.21%
|
48.14
+51.73%
|
31.73
-11.41%
|
35.81
|
| Selling General And Administration |
|
17.68
-1.56%
|
17.96
+81.86%
|
9.88
-1.86%
|
10.06
|
| General And Administrative Expense |
|
17.68
-1.56%
|
17.96
+81.86%
|
9.88
-1.86%
|
10.06
|
| Other Gand A |
|
17.68
-1.56%
|
17.96
+81.86%
|
9.88
-1.86%
|
10.06
|
| Total Expenses |
|
36.84
-44.28%
|
66.10
+58.88%
|
41.60
-9.31%
|
45.88
|
| Operating Income |
|
16.90
+125.57%
|
-66.10
-36.98%
|
-48.26
-23.02%
|
-39.23
|
| Total Operating Income As Reported |
|
16.90
+125.57%
|
-66.10
-36.98%
|
-48.26
-23.02%
|
-39.23
|
| EBITDA |
|
31.31
+170.36%
|
-44.50
+6.82%
|
-47.76
-22.91%
|
-38.85
|
| Normalized EBITDA |
|
19.57
+132.79%
|
-59.69
-43.61%
|
-41.56
-14.02%
|
-36.45
|
| Reconciled Depreciation |
|
0.39
-19.71%
|
0.49
-2.40%
|
0.50
+34.86%
|
0.37
|
| EBIT |
|
30.92
+168.73%
|
-44.99
+6.77%
|
-48.26
-23.02%
|
-39.23
|
| Total Unusual Items |
|
11.74
-22.73%
|
15.19
+345.28%
|
-6.19
-157.83%
|
-2.40
|
| Total Unusual Items Excluding Goodwill |
|
11.74
-22.73%
|
15.19
+345.28%
|
-6.19
-157.83%
|
-2.40
|
| Special Income Charges |
|
11.74
+1776.71%
|
-0.70
|
—
|
—
|
| Write Off |
|
—
|
0.70
|
—
|
—
|
| Net Income |
|
29.82
+162.47%
|
-47.73
+11.18%
|
-53.74
-25.54%
|
-42.81
|
| Pretax Income |
|
29.82
+164.71%
|
-46.09
+13.74%
|
-53.42
-24.98%
|
-42.75
|
| Net Non Operating Interest Income Expense |
|
1.10
-60.71%
|
2.80
|
—
|
—
|
| Interest Expense Non Operating |
|
1.10
+0.00%
|
1.10
|
—
|
—
|
| Net Interest Income |
|
1.10
-60.71%
|
2.80
|
—
|
—
|
| Interest Expense |
|
1.10
+0.00%
|
1.10
|
—
|
—
|
| Interest Income Non Operating |
|
2.20
-43.59%
|
3.90
|
—
|
—
|
| Interest Income |
|
2.20
-43.59%
|
3.90
|
—
|
—
|
| Other Income Expense |
|
11.82
-31.34%
|
17.21
+432.98%
|
-5.17
-46.79%
|
-3.52
|
| Other Non Operating Income Expenses |
|
0.08
-95.95%
|
2.02
+97.95%
|
1.02
+191.34%
|
-1.12
|
| Gain On Sale Of Security |
|
—
|
15.89
+356.58%
|
-6.19
-157.83%
|
-2.40
|
| Tax Provision |
|
0.00
-100.00%
|
0.02
-93.40%
|
0.32
+412.90%
|
0.06
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
+0.00%
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
-100.00%
|
3.19
+345.28%
|
-1.30
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
29.82
+162.47%
|
-47.73
+11.18%
|
-53.74
-25.54%
|
-42.81
|
| Net Income From Continuing Operation Net Minority Interest |
|
29.82
+162.47%
|
-47.73
+11.18%
|
-53.74
-25.54%
|
-42.81
|
| Net Income From Continuing And Discontinued Operation |
|
29.82
+162.47%
|
-47.73
+11.18%
|
-53.74
-25.54%
|
-42.81
|
| Net Income Continuous Operations |
|
29.82
+162.47%
|
-47.73
+11.18%
|
-53.74
-25.54%
|
-42.81
|
| Normalized Income |
|
18.08
+130.27%
|
-59.73
-22.28%
|
-48.85
-20.90%
|
-40.41
|
| Net Income Common Stockholders |
|
29.82
+162.47%
|
-47.73
+11.18%
|
-53.74
-25.54%
|
-42.81
|
| Diluted EPS |
|
—
|
-6.58
-46.06%
|
-4.51
-25.54%
|
-3.59
|
| Basic EPS |
|
—
|
-5.12
-13.65%
|
-4.51
-25.54%
|
-3.59
|
| Basic Average Shares |
|
—
|
9.32
-21.87%
|
11.93
+0.00%
|
11.93
|
| Diluted Average Shares |
|
—
|
9.66
-19.04%
|
11.93
+0.00%
|
11.93
|
| Diluted NI Availto Com Stockholders |
|
29.82
+146.94%
|
-63.53
-18.22%
|
-53.74
-25.54%
|
-42.81
|
| Average Dilution Earnings |
|
—
|
-15.80
|
—
|
—
|
| Earnings From Equity Interest Net Of Tax |
|
0.00
+100.00%
|
-1.62
|
0.00
|
—
|
| Gain On Sale Of PPE |
|
11.74
|
0.00
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
61.78
-33.09%
|
92.33
+96.21%
|
47.06
-23.82%
|
61.77
|
| Current Assets |
|
55.05
-32.77%
|
81.88
+185.13%
|
28.72
-38.71%
|
46.85
|
| Cash Cash Equivalents And Short Term Investments |
|
48.30
-38.05%
|
77.97
+204.35%
|
25.62
-41.64%
|
43.89
|
| Cash And Cash Equivalents |
|
48.30
-38.05%
|
77.97
+204.35%
|
25.62
-41.64%
|
43.89
|
| Receivables |
|
5.39
+871.53%
|
0.56
-26.49%
|
0.76
-29.04%
|
1.06
|
| Other Receivables |
|
4.84
|
—
|
—
|
0.12
|
| Taxes Receivable |
|
0.56
+0.00%
|
0.56
-26.49%
|
0.76
-20.36%
|
0.95
|
| Prepaid Assets |
|
1.34
-54.71%
|
2.96
+30.96%
|
2.26
+29.20%
|
1.75
|
| Other Current Assets |
|
0.02
-94.95%
|
0.40
+377.11%
|
0.08
-43.15%
|
0.15
|
| Total Non Current Assets |
|
6.73
-35.67%
|
10.46
-43.00%
|
18.34
+22.92%
|
14.92
|
| Net PPE |
|
6.08
-14.28%
|
7.09
-12.26%
|
8.08
-11.82%
|
9.17
|
| Gross PPE |
|
7.92
-7.28%
|
8.54
-5.57%
|
9.05
-6.06%
|
9.63
|
| Accumulated Depreciation |
|
-1.84
-26.91%
|
-1.45
-50.41%
|
-0.97
-106.85%
|
-0.47
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.44
+0.00%
|
0.44
+3.29%
|
0.43
+0.00%
|
0.43
|
| Other Properties |
|
6.48
-8.76%
|
7.10
-7.54%
|
7.68
-7.12%
|
8.27
|
| Leases |
|
1.00
+0.00%
|
1.00
+6.49%
|
0.94
+0.53%
|
0.94
|
| Investments And Advances |
|
0.00
-100.00%
|
2.60
|
0.00
|
—
|
| Long Term Equity Investment |
|
0.00
-100.00%
|
2.60
|
0.00
|
—
|
| Non Current Deferred Assets |
|
—
|
0.00
-100.00%
|
3.91
|
—
|
| Non Current Prepaid Assets |
|
0.00
-100.00%
|
0.12
-82.84%
|
0.68
|
—
|
| Other Non Current Assets |
|
0.65
+0.00%
|
0.65
-88.59%
|
5.67
-1.48%
|
5.75
|
| Total Liabilities Net Minority Interest |
|
19.76
-77.20%
|
86.66
-62.32%
|
229.98
+19.48%
|
192.49
|
| Current Liabilities |
|
11.35
-31.09%
|
16.46
+16.70%
|
14.11
-75.62%
|
57.87
|
| Payables And Accrued Expenses |
|
1.93
-72.69%
|
7.07
-27.00%
|
9.69
+26.34%
|
7.67
|
| Payables |
|
0.88
-70.59%
|
2.99
-21.01%
|
3.78
+88.73%
|
2.00
|
| Accounts Payable |
|
0.88
-70.59%
|
2.99
-13.81%
|
3.47
+141.67%
|
1.44
|
| Current Accrued Expenses |
|
1.05
-74.22%
|
4.08
-30.83%
|
5.91
+4.25%
|
5.67
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
2.49
-10.64%
|
2.78
-7.36%
|
3.00
+7.60%
|
2.79
|
| Total Tax Payable |
|
—
|
0.00
-100.00%
|
0.32
-44.56%
|
0.57
|
| Current Debt And Capital Lease Obligation |
|
6.93
+86.79%
|
3.71
+161.94%
|
1.42
-95.69%
|
32.87
|
| Current Debt |
|
6.24
+101.32%
|
3.10
+252.73%
|
0.88
-97.29%
|
32.40
|
| Other Current Borrowings |
|
6.24
+101.32%
|
3.10
+252.73%
|
0.88
-97.29%
|
32.40
|
| Current Capital Lease Obligation |
|
0.69
+13.24%
|
0.61
+13.75%
|
0.54
+14.23%
|
0.47
|
| Current Deferred Liabilities |
|
—
|
—
|
—
|
14.53
|
| Current Deferred Revenue |
|
—
|
—
|
—
|
14.53
|
| Other Current Liabilities |
|
—
|
2.90
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
8.42
-88.01%
|
70.19
-67.48%
|
215.87
+60.35%
|
134.62
|
| Long Term Debt And Capital Lease Obligation |
|
8.42
-44.60%
|
15.19
-69.26%
|
49.42
+316.80%
|
11.86
|
| Long Term Debt |
|
3.47
-63.66%
|
9.56
-77.87%
|
43.18
+751.26%
|
5.07
|
| Long Term Capital Lease Obligation |
|
4.94
-12.30%
|
5.64
-9.80%
|
6.25
-7.93%
|
6.79
|
| Non Current Deferred Liabilities |
|
—
|
—
|
—
|
11.32
|
| Non Current Deferred Revenue |
|
—
|
—
|
—
|
11.32
|
| Other Non Current Liabilities |
|
—
|
55.00
+0.00%
|
55.00
|
—
|
| Preferred Securities Outside Stock Equity |
|
—
|
0.00
-100.00%
|
111.44
+0.00%
|
111.44
|
| Stockholders Equity |
|
42.01
+640.33%
|
5.67
+103.10%
|
-182.92
-39.94%
|
-130.71
|
| Common Stock Equity |
|
42.01
+640.33%
|
5.67
+103.10%
|
-182.92
-39.94%
|
-130.71
|
| Capital Stock |
|
0.00
+0.00%
|
0.00
+100.00%
|
0.00
+0.00%
|
0.00
|
| Common Stock |
|
0.00
+0.00%
|
0.00
+100.00%
|
0.00
+0.00%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
—
|
111.44
|
| Share Issued |
|
12.86
+5.41%
|
12.20
+2.25%
|
11.93
+0.00%
|
11.93
|
| Ordinary Shares Number |
|
12.86
+5.41%
|
12.20
+2.25%
|
11.93
+0.00%
|
11.93
|
| Additional Paid In Capital |
|
247.00
+2.71%
|
240.49
+5682.33%
|
4.16
+58.44%
|
2.62
|
| Retained Earnings |
|
-204.99
+12.70%
|
-234.81
-25.51%
|
-187.08
-40.31%
|
-133.34
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
0.00
|
0.00
|
—
|
| Total Equity Gross Minority Interest |
|
42.01
+640.33%
|
5.67
+103.10%
|
-182.92
-39.94%
|
-130.71
|
| Total Capitalization |
|
45.49
+198.65%
|
15.23
+110.90%
|
-139.75
-11.23%
|
-125.64
|
| Working Capital |
|
43.70
-33.19%
|
65.41
+347.81%
|
14.61
+232.65%
|
-11.01
|
| Invested Capital |
|
51.72
+182.20%
|
18.33
+113.20%
|
-138.87
-48.94%
|
-93.24
|
| Total Debt |
|
15.34
-18.82%
|
18.90
-62.82%
|
50.84
+13.66%
|
44.73
|
| Net Debt |
|
—
|
—
|
18.44
|
—
|
| Capital Lease Obligations |
|
5.64
-9.80%
|
6.25
-7.93%
|
6.79
-6.49%
|
7.26
|
| Net Tangible Assets |
|
42.01
+640.33%
|
5.67
+103.10%
|
-182.92
-39.94%
|
-130.71
|
| Tangible Book Value |
|
42.01
+640.33%
|
5.67
+103.10%
|
-182.92
-39.94%
|
-130.71
|
| Interest Payable |
|
—
|
—
|
—
|
0.38
|
| Preferred Stock Equity |
|
—
|
—
|
—
|
111.44
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-33.54
+50.46%
|
-67.72
-262.56%
|
-18.68
-70.46%
|
-10.96
|
| Cash Flow From Continuing Operating Activities |
|
-33.54
+50.46%
|
-67.72
-262.56%
|
-18.68
-70.46%
|
-10.96
|
| Net Income From Continuing Operations |
|
29.82
+162.47%
|
-47.73
+11.18%
|
-53.74
-25.54%
|
-42.81
|
| Depreciation Amortization Depletion |
|
0.39
-19.71%
|
0.49
-2.40%
|
0.50
+34.86%
|
0.37
|
| Depreciation |
|
0.39
-19.71%
|
0.49
-2.40%
|
0.50
+34.86%
|
0.37
|
| Depreciation And Amortization |
|
0.39
-19.71%
|
0.49
-2.40%
|
0.50
+34.86%
|
0.37
|
| Other Non Cash Items |
|
-53.31
-3688.84%
|
-1.41
-322.98%
|
0.63
-27.97%
|
0.88
|
| Stock Based Compensation |
|
5.25
+19.81%
|
4.39
+207.14%
|
1.43
+15.35%
|
1.24
|
| Asset Impairment Charge |
|
0.07
-89.04%
|
0.68
|
0.00
|
—
|
| Operating Gains Losses |
|
-11.74
-822.28%
|
1.62
|
—
|
0.02
|
| Unrealized Gain Loss On Investment Securities |
|
0.00
+100.00%
|
-15.89
-356.58%
|
6.19
+157.83%
|
2.40
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
0.02
|
| Change In Working Capital |
|
-4.04
+58.10%
|
-9.64
-136.62%
|
26.32
-2.33%
|
26.94
|
| Change In Prepaid Assets |
|
1.90
+586.96%
|
0.28
+393.62%
|
-0.09
+92.22%
|
-1.21
|
| Change In Payables And Accrued Expense |
|
-5.44
+37.90%
|
-8.76
-492.34%
|
2.23
-11.32%
|
2.52
|
| Change In Accrued Expense |
|
-3.33
+56.86%
|
-7.71
-3976.38%
|
0.20
-94.70%
|
3.76
|
| Change In Payable |
|
-2.11
-102.30%
|
-1.04
-151.30%
|
2.03
+263.82%
|
-1.24
|
| Change In Account Payable |
|
-2.11
-102.30%
|
-1.04
-151.30%
|
2.03
+263.82%
|
-1.24
|
| Change In Other Working Capital |
|
—
|
—
|
-25.85
-200.00%
|
25.85
|
| Change In Other Current Assets |
|
0.12
-69.95%
|
0.39
+108.57%
|
-4.50
-2409.23%
|
0.20
|
| Change In Other Current Liabilities |
|
-0.61
+60.31%
|
-1.54
-102.83%
|
54.53
+13432.27%
|
-0.41
|
| Investing Cash Flow |
|
7.00
-64.87%
|
19.93
+398600.00%
|
-0.01
+99.80%
|
-2.47
|
| Cash Flow From Continuing Investing Activities |
|
7.00
-64.87%
|
19.93
+398600.00%
|
-0.01
+99.80%
|
-2.47
|
| Net PPE Purchase And Sale |
|
0.00
+100.00%
|
-0.07
-1400.00%
|
-0.01
+99.80%
|
-2.47
|
| Purchase Of PPE |
|
0.00
+100.00%
|
-0.07
-1400.00%
|
-0.01
+99.80%
|
-2.48
|
| Sale Of PPE |
|
—
|
—
|
—
|
0.02
|
| Capital Expenditure |
|
—
|
-0.07
-1400.00%
|
-0.01
+99.80%
|
-2.48
|
| Net Investment Purchase And Sale |
|
0.00
-100.00%
|
20.00
|
0.00
|
—
|
| Sale Of Investment |
|
0.00
-100.00%
|
20.00
|
0.00
|
—
|
| Net Other Investing Changes |
|
7.00
|
—
|
—
|
—
|
| Financing Cash Flow |
|
-3.12
-103.28%
|
95.14
+23333.00%
|
0.41
-98.65%
|
30.07
|
| Cash Flow From Continuing Financing Activities |
|
-3.12
-103.28%
|
95.14
+23333.00%
|
0.41
-98.65%
|
30.07
|
| Net Issuance Payments Of Debt |
|
-3.12
-144.64%
|
7.00
+2233.33%
|
0.30
-99.00%
|
30.00
|
| Issuance Of Debt |
|
0.00
-100.00%
|
7.00
+27.27%
|
5.50
-81.67%
|
30.00
|
| Repayment Of Debt |
|
-3.12
|
0.00
+100.00%
|
-5.20
|
—
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
7.00
+27.27%
|
5.50
|
—
|
| Long Term Debt Payments |
|
-3.12
|
0.00
+100.00%
|
-5.20
|
—
|
| Net Long Term Debt Issuance |
|
-3.12
-144.64%
|
7.00
+2233.33%
|
0.30
|
—
|
| Short Term Debt Issuance |
|
—
|
—
|
—
|
30.00
|
| Net Short Term Debt Issuance |
|
—
|
—
|
—
|
30.00
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
42.00
|
0.00
-100.00%
|
0.07
|
| Proceeds From Stock Option Exercised |
|
0.00
-100.00%
|
1.69
+1498.11%
|
0.11
+53.62%
|
0.07
|
| Net Other Financing Charges |
|
—
|
44.44
|
—
|
—
|
| Changes In Cash |
|
-29.67
-162.66%
|
47.35
+359.07%
|
-18.28
-209.79%
|
16.65
|
| Beginning Cash Position |
|
78.61
+151.45%
|
31.26
-36.89%
|
49.54
+50.60%
|
32.89
|
| End Cash Position |
|
48.94
-37.74%
|
78.61
+151.45%
|
31.26
-36.89%
|
49.54
|
| Free Cash Flow |
|
-33.54
+50.52%
|
-67.79
-262.86%
|
-18.68
-38.98%
|
-13.44
|
| Interest Paid Supplemental Data |
|
0.96
+12.27%
|
0.86
+102.84%
|
0.42
|
—
|
| Amortization Of Securities |
|
0.00
+100.00%
|
-0.22
|
0.00
|
—
|
| Common Stock Issuance |
|
0.00
-100.00%
|
42.00
|
0.00
-100.00%
|
0.07
|
| Earnings Losses From Equity Investments |
|
0.00
-100.00%
|
1.62
|
0.00
|
—
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
42.00
|
0.00
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-27 View
- 42026-03-20 View
- 42026-03-20 View
- 42026-03-20 View
- 10-K2026-03-10 View
- 8-K2026-03-10 View
- 42026-02-27 View
- 42026-02-27 View
- 42026-02-27 View
- 8-K2026-02-17 View
- 42026-01-30 View
- 42026-01-30 View
- 42026-01-30 View
- 8-K2025-12-19 View
- 42025-12-04 View
- 42025-12-04 View
- 8-K2025-12-01 View
- 10-Q2025-11-13 View
- 8-K2025-11-13 View
- 42025-10-27 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|